Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells

BMC Medical Genomics

Volumn 2, Issue , 2009, Pages

  Gurevich, Michael ^a   Tuller, Tamir ^a   Rubinstein, Udi ^a   Or Bach, Rotem ^a   Achiron, Anat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE;

ACCURACY; ACUTE DISEASE; ADULT; ARTICLE; BLOOD CELL; CLINICAL EVALUATION; DISEASE ACTIVITY; GENE; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; RELAPSE;

EID: 69049102091     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-2-46     Document Type: Article

References (55)

1. Myasthenia gravis: past, present, and future. BM Conti-Fine M Milani HJ Kaminski, J Clin Invest 2006 116 11 2843 2854 17080188
2. Neurological lupus erythematosus with tonic seizures simulating multiple sclerosis. M Hutchinson B Bresnihan, J Neurol Neurosurg Psychiatry 1983 46 6 583 585 6875598
3. Rheumatoid arthritis: diagnosis and management. V Majithia SA Geraci, Am J Med 2007 120 11 936 939 17976416
4. Inflammatory bowel disease. SB Hanauer, N Engl J Med 1996 334 13 841 848 8596552
5. Multiple sclerosis: common management issues. E McDonald, Aust Fam Physician 1992 21 10 1421 1424 1280093
6. Multiple sclerosis: the disease and its manifestations. WI McDonald MA Ron, Philos Trans R Soc Lond B Biol Sci 1999 354 1390 1615 1622 10603614
7. Relapse, remission, and progression in multiple sclerosis. WI McDonald, N Engl J Med 2000 343 20 1486 1487 11078776
8. Short-term prognosis in early relapsing-remitting multiple sclerosis. TF Scott CJ Schramke J Novero C Chieffe, Neurology 2000 55 5 689 693 10980735
9. Predictors of relapse rate in MS clinical trials. U Held L Heigenhauser C Shang L Kappos C Polman, Neurology 2005 65 11 1769 1773 16344520
10. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. R Bergamaschi C Berzuini A Romani V Cosi, J Neurol Sci 2001 189 1-2 13 21 11535229
11. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. R Bergamaschi, Expert Rev Neurother 2006 6 3 357 364 16533140
12. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. R Bergamaschi S Quaglini M Trojano MP Amato E Tavazzi D Paolicelli V Zipoli A Romani A Fuiani E Portaccio, et al. J Neurol Neurosurg Psychiatry 2007 78 7 757 759 17220286
13. The natural history of multiple sclerosis. BG Weinshenker GC Ebers, Can J Neurol Sci 1987 14 3 255 261 3311324
14. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. JG Phadke, Brain 1990 113 Pt 6 1597 1628 2276037
15. Prediction of outcome in multiple sclerosis based on multivariate models. B Runmarker C Andersson A Oden O Andersen, J Neurol 1994 241 10 597 604 7836963
16. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. F Allantaz D Chaussabel D Stichweh L Bennett W Allman A Mejias M Ardura W Chung C Wise K Palucka, et al. J Exp Med 2007 204 9 2131 2144 17724127
17. Factors associated with functional disability in patients with rheumatoid arthritis. O Oken G Batur R Gunduz RZ Yorgancioglu, Rheumatol Int 2008 29 2 163 166 18696072
18. Antibodies as predictors of complex autoimmune diseases. A Vojdani, Int J Immunopathol Pharmacol 2008 21 2 267 278 18547471
19. CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. A Martinez-Yelamos A Rovira R Sanchez-Valle S Martinez-Yelamos M Tintore Y Blanco F Graus X Montalban T Arbizu A Saiz, J Neurol 2004 251 10 1278 1279 15503113
20. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. A Martinez-Yelamos A Saiz J Bas JJ Hernandez F Graus T Arbizu, Neurosci Lett 2004 363 1 14 17 15157986
21. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. T Berger P Rubner F Schautzer R Egg H Ulmer I Mayringer E Dilitz F Deisenhammer M Reindl, N Engl J Med 2003 349 2 139 145 12853586
22. Lack of association between antimyelin antibodies and progression to multiple sclerosis. T Berger M Reindl, N Engl J Med 2007 356 18 1888 1889 17476020
23. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Kuhle RL Lindberg A Regeniter M Mehling F Hoffmann M Reindl T Berger EW Radue D Leppert L Kappos, J Neurol 2007 254 2 160 168 17334662
24. Prognostic factors in multiple sclerosis. R Bergamaschi, Int Rev Neurobiol 2007 79 423 447 17531853
25. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. M Sailer JI O'Riordan AJ Thompson DP Kingsley DG MacManus WI McDonald DH Miller, Neurology 1999 52 3 599 606 10025795
26. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. A Achiron M Gurevich Y Snir E Segal M Mandel, Clin Exp Immunol 2007 149 2 235 242 17488294
27. Transcription-based prediction of response to IFNbeta using supervised computational methods. SE Baranzini P Mousavi J Rio SJ Caillier A Stillman P Villoslada MM Wyatt M Comabella LD Greller R Somogyi, et al. PLoS Biol 2005 3 1 e2 15630474
28. MR imaging in white matter diseases of the brain and spinal cord. M Filippi N De Stefano V Dousset JCE McGowan, Berlin: Springer 2005 219
29. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. WI McDonald A Compston G Edan D Goodkin HP Hartung FD Lublin HF McFarland DW Paty CH Polman SC Reingold, et al. Ann Neurol 2001 50 1 121 127 11456302
30. Revised diagnostic criteria for neuromyelitis optica. DM Wingerchuk VA Lennon SJ Pittock CF Lucchinetti BG Weinshenker, Neurology 2006 66 10 1485 1489 16717206
31. A Tutorial on Support Vector Machines for Pattern Recognition. CJC Burges, Data Mining and Knowledge Discovery 1998 2 121 167
32. Overfitting and undercomputing in machine learning. T Dietterich, ACM Computing Surveys 1995 27 3 326 327
33. Estimating the error rate of a prediction rule improvement on cross-validation. B Efron, Journal of the American Statistical Association 1983 78 382 316 330
34. Predictive Inference: An Introduction. S Geisser, New York: CRC Press 1993
35. TGFbeta directs gene expression of activated microglia to an anti-inflammatory phenotype strongly focusing on chemokine genes and cell migratory genes. R Paglinawan U Malipiero R Schlapbach K Frei W Reith A Fontana, Glia 2003 44 3 219 231 14603463
36. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. JJ Bright S Sriram, J Immunol 1998 161 4 1772 1777 9712043
37. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. M Centola G Wood DM Frucht J Galon M Aringer C Farrell DW Kingma ME Horwitz E Mansfield SM Holland, et al. Blood 2000 95 10 3223 3231 10807793
38. Effects of carbonic anhydrase II (CAII) deficiency on CNS structure and function in the myelin-deficient CAII-deficient double mutant mouse. W Cammer H Zhang FA Tansey, J Neurosci Res 1995 40 4 451 457 7616606
39. Sam68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. J Cote FM Boisvert MC Boulanger MT Bedford S Richard, Mol Biol Cell 2003 14 1 274 287 12529443
40. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. C Tissot N Mechti, J Biol Chem 1995 270 25 14891 14898 7797467
41. Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. M Andrianifahanana A Agrawal AP Singh N Moniaux I van Seuningen JP Aubert J Meza SK Batra, Oncogene 2005 24 40 6143 6154 16007204
42. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. BW Baron J Anastasi MJ Thirman Y Furukawa S Fears DC Kim F Simone M Birkenbach A Montag A Sadhu, et al. Proc Natl Acad Sci USA 2002 99 5 2860 2865 11854457
43. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. T Bouwmeester A Bauch H Ruffner PO Angrand G Bergamini K Croughton C Cruciat D Eberhard J Gagneur S Ghidelli, et al. Nat Cell Biol 2004 6 2 97 105 14743216
44. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. A Deb SJ Haque T Mogensen RH Silverman BR Williams, J Immunol 2001 166 10 6170 6180 11342638
45. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. C Klein JI Paul K Sauve MM Schmidt L Arcangeli J Ransom J Trueheart JP Manfredi JR Broach AJ Murphy, Nature biotechnology 1998 16 13 1334 1337 9853614
46. The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. Y Le H Yazawa W Gong Z Yu VJ Ferrans PM Murphy JM Wang, J Immunol 2001 166 3 1448 1451 11160182
47. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. FM Batliwalla W Li CT Ritchlin X Xiao M Brenner T Laragione T Shao R Durham S Kemshetti E Schwarz, et al. Molecular medicine (Cambridge, Mass) 2005 11 1-12 21 29 16622521
48. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. CJ Barnes F Li M Mandal Z Yang AA Sahin R Kumar, Cancer research 2002 62 5 1251 1255 11888885
49. TGF-beta1 disrupts endotoxin signaling in microglial cells through Smad3 and MAPK pathways. Y Le P Iribarren W Gong Y Cui X Zhang JM Wang, J Immunol 2004 173 2 962 968 15240683
50. Phosphoproteome profiling of transforming growth factor (TGF)-beta signaling: abrogation of TGFbeta1-dependent phosphorylation of transcription factor-II-I (TFII-I) enhances cooperation of TFII-I and Smad3 in transcription. T Stasyk A Dubrovska M Lomnytska I Yakymovych C Wernstedt CH Heldin U Hellman S Souchelnytskyi, Mol Biol Cell 2005 16 10 4765 4780 16055503
51. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. IFNB Multiple Sclerosis Study Group E-U, Neurology 1993 43 4 655 661 8469318
52. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. (Commanditaire) IMSG, University of British Columbia MS/MRI Analysis Group E-UC, Neurology 1995 45 7 1277 1285 7617182
53. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Group PPoRaDbIb-aSiMSS, Lancet 1998 352 9139 1498 1504 9820297
54. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Group UMMS, IFNB Multiple Sclerosis Study Group E-U, Neurology 2001 56 12 1628 1636 11425926
55. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). LD Jacobs DL Cookfair RA Rudick RM Herndon JR Richert AM Salazar JS Fischer DE Goodkin CV Granger JH Simon, et al. Ann Neurol 1996 39 3 285 294 8602746